Qian Weibin, Hasegawa Junichi, Cai Xinrui, Yang Jie, Ishihara Yoshitaka, Ping Bingqiong, Tsuno Satoshi, Endo Yusuke, Matsuda Akiko, Miura Norimasa
Division of Pharmacotherapeutics, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan.
Yonago Acta Med. 2016 Mar;59(1):67-80. Epub 2016 Apr 1.
Ogi, one main component of boiogito (BOT), is reported to have an effect on hypercholesterolemia and NAFLD. In this experiment, we examined effects of ogi on the progression of hypercholesterolemia and fatty liver induced by high-cholesterol diet in rats and compared with the effects of ogi combined with ginger or hesperidin.
Hypercholesterolemia and fatty liver were induced by a high cholesterol diet in rats. Extract of ogi, ogi with hesperidin, and ogi with ginger were added to the high-cholesterol diet, respectively. Ezetimibe was also added to the high-cholesterol diet as a positive control. After 6 and 12 weeks, body, liver and adipose tissue weights, blood chemistry, lipid-related and inflammatory-related factors were examined.
The high cholesterol diet increased body, liver and adipose tissue weights, and serum cholesterol concentrations. Ogi, ogi with hesperidin or ginger and ezetimibe improved them. In the histological examinations, we observed a significant improvement after treatment. The lipid-related factors (RBP4, HFABP and CFABP) were improved by treatment. Biomarkers of cholesterol synthesis (lathosterol) and absorption (campesterol, beta-sitosterol) were lower in the treatment groups. Inflammatory-related factors (MCP1, CCR2 and TNF-alpha) and ICAM-1 were ameliorated after treatment, especially by ogi with ginger.
Ogi, ogi with hesperidin or ginger have a similar effect of BOT and ezetimibe on hypercholesterolemia and fatty liver. Ogi with ginger reveals a stronger additive effect with no significant difference. However, as for the anti-inflammatory (MCP1, CCR2 and TNF-alpha) and anti-arteriosclerotic (ICAM-1) effects, additive effects of ogi with ginger are more potent than that of ogi alone or ezetimibe.
据报道，生物发酵剂（BOT）的主要成分之一奥吉对高胆固醇血症和非酒精性脂肪性肝病有影响。在本实验中，我们研究了奥吉对高胆固醇饮食诱导的大鼠高胆固醇血症和脂肪肝进展的影响，并与奥吉联合生姜或橙皮苷的效果进行了比较。
用高胆固醇饮食诱导大鼠产生高胆固醇血症和脂肪肝。将奥吉提取物、奥吉与橙皮苷、奥吉与生姜分别添加到高胆固醇饮食中。依泽替米贝也添加到高胆固醇饮食中作为阳性对照。6周和12周后，检测体重、肝脏和脂肪组织重量、血液生化指标、脂质相关和炎症相关因子。
高胆固醇饮食增加了体重、肝脏和脂肪组织重量以及血清胆固醇浓度。奥吉、奥吉与橙皮苷或生姜以及依泽替米贝改善了这些指标。在组织学检查中，我们观察到治疗后有显著改善。治疗后脂质相关因子（视黄醇结合蛋白4、心脏型脂肪酸结合蛋白和小肠脂肪酸结合蛋白）得到改善。治疗组中胆固醇合成（羊毛甾醇）和吸收（菜油甾醇、β-谷甾醇）的生物标志物较低。治疗后炎症相关因子（单核细胞趋化蛋白1、趋化因子受体2和肿瘤坏死因子-α）和细胞间黏附分子-1有所改善，尤其是奥吉与生姜联合使用时。
奥吉、奥吉与橙皮苷或生姜对高胆固醇血症和脂肪肝的作用与生物发酵剂和依泽替米贝相似。奥吉与生姜联合使用显示出更强的相加作用，且无显著差异。然而，在抗炎（单核细胞趋化蛋白1、趋化因子受体2和肿瘤坏死因子-α）和抗动脉粥样硬化（细胞间黏附分子-1）作用方面，奥吉与生姜的相加作用比单独使用奥吉或依泽替米贝更强。
